G2 Investment Partners Management LLC lessened its stake in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 45.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 133,167 shares of the company's stock after selling 109,041 shares during the quarter. G2 Investment Partners Management LLC owned about 0.72% of OptimizeRx worth $647,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of OPRX. Whetstone Capital Advisors LLC purchased a new stake in OptimizeRx in the fourth quarter valued at $6,563,000. Royce & Associates LP acquired a new stake in shares of OptimizeRx during the fourth quarter worth about $5,198,000. Kennedy Capital Management LLC lifted its holdings in shares of OptimizeRx by 57.8% in the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock valued at $2,887,000 after purchasing an additional 217,676 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of OptimizeRx in the 4th quarter valued at about $673,000. Finally, Marshall Wace LLP acquired a new position in OptimizeRx during the fourth quarter worth approximately $653,000. Institutional investors and hedge funds own 76.47% of the company's stock.
OptimizeRx Stock Up 4.3 %
Shares of OptimizeRx stock opened at $9.88 on Friday. OptimizeRx Co. has a one year low of $3.78 and a one year high of $14.13. The company has a market cap of $182.77 million, a P/E ratio of -7.43 and a beta of 1.28. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The firm has a fifty day moving average of $8.05 and a two-hundred day moving average of $6.27.
Insider Buying and Selling
In other OptimizeRx news, Director James Paul Lang acquired 321,408 shares of the stock in a transaction on Friday, March 14th. The shares were bought at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the acquisition, the director now owns 389,452 shares of the company's stock, valued at $2,959,835.20. This trade represents a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 6.10% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
OPRX has been the subject of several research analyst reports. B. Riley raised OptimizeRx to a "strong-buy" rating in a report on Wednesday, March 12th. JMP Securities reiterated a "market outperform" rating and set a $8.00 price target on shares of OptimizeRx in a research note on Thursday, February 6th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, OptimizeRx has a consensus rating of "Moderate Buy" and a consensus target price of $9.06.
Check Out Our Latest Analysis on OptimizeRx
OptimizeRx Profile
(
Free Report)
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Further Reading
Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Co. (NASDAQ:OPRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
